TR200201169T2 - 2-(4,6-Dimetilpirimidinil-2-oksi)-3- [2-(3,4-dimetoksifenil)etoksi]-3,3-difenilpropiyonat ve endotelin antagonist olarak kullanılması - Google Patents
2-(4,6-Dimetilpirimidinil-2-oksi)-3- [2-(3,4-dimetoksifenil)etoksi]-3,3-difenilpropiyonat ve endotelin antagonist olarak kullanılmasıInfo
- Publication number
- TR200201169T2 TR200201169T2 TR2002/01169T TR200201169T TR200201169T2 TR 200201169 T2 TR200201169 T2 TR 200201169T2 TR 2002/01169 T TR2002/01169 T TR 2002/01169T TR 200201169 T TR200201169 T TR 200201169T TR 200201169 T2 TR200201169 T2 TR 200201169T2
- Authority
- TR
- Turkey
- Prior art keywords
- dimethylpyrimidinyl
- diphenylpropionate
- endothelin
- dimethoxyphenyl
- antagonist
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19951671A DE19951671A1 (de) | 1999-10-27 | 1999-10-27 | 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200201169T2 true TR200201169T2 (tr) | 2002-09-23 |
Family
ID=7927001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/01169T TR200201169T2 (tr) | 1999-10-27 | 2000-10-17 | 2-(4,6-Dimetilpirimidinil-2-oksi)-3- [2-(3,4-dimetoksifenil)etoksi]-3,3-difenilpropiyonat ve endotelin antagonist olarak kullanılması |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1228047A1 (cs) |
| JP (1) | JP2003512460A (cs) |
| KR (1) | KR20020047301A (cs) |
| CN (1) | CN1384822A (cs) |
| AU (1) | AU1272701A (cs) |
| BG (1) | BG106700A (cs) |
| BR (1) | BR0015112A (cs) |
| CA (1) | CA2389012A1 (cs) |
| CZ (1) | CZ20021485A3 (cs) |
| DE (1) | DE19951671A1 (cs) |
| HU (1) | HUP0203476A3 (cs) |
| IL (1) | IL149312A0 (cs) |
| MX (1) | MXPA02004071A (cs) |
| NO (1) | NO20021986L (cs) |
| SK (1) | SK5962002A3 (cs) |
| TR (1) | TR200201169T2 (cs) |
| WO (1) | WO2001030767A1 (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2532650A3 (en) | 2004-06-24 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
-
1999
- 1999-10-27 DE DE19951671A patent/DE19951671A1/de not_active Withdrawn
-
2000
- 2000-10-17 TR TR2002/01169T patent/TR200201169T2/xx unknown
- 2000-10-17 CZ CZ20021485A patent/CZ20021485A3/cs unknown
- 2000-10-17 IL IL14931200A patent/IL149312A0/xx unknown
- 2000-10-17 WO PCT/EP2000/010202 patent/WO2001030767A1/de not_active Application Discontinuation
- 2000-10-17 BR BR0015112-2A patent/BR0015112A/pt not_active IP Right Cessation
- 2000-10-17 SK SK596-2002A patent/SK5962002A3/sk unknown
- 2000-10-17 EP EP00974404A patent/EP1228047A1/de not_active Withdrawn
- 2000-10-17 AU AU12727/01A patent/AU1272701A/en not_active Abandoned
- 2000-10-17 CN CN00814871A patent/CN1384822A/zh active Pending
- 2000-10-17 HU HU0203476A patent/HUP0203476A3/hu unknown
- 2000-10-17 KR KR1020027005457A patent/KR20020047301A/ko not_active Ceased
- 2000-10-17 CA CA002389012A patent/CA2389012A1/en not_active Abandoned
- 2000-10-17 JP JP2001533121A patent/JP2003512460A/ja not_active Abandoned
- 2000-10-17 MX MXPA02004071A patent/MXPA02004071A/es unknown
-
2002
- 2002-04-26 NO NO20021986A patent/NO20021986L/no not_active Application Discontinuation
- 2002-05-14 BG BG106700A patent/BG106700A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02004071A (es) | 2002-10-11 |
| NO20021986D0 (no) | 2002-04-26 |
| AU1272701A (en) | 2001-05-08 |
| SK5962002A3 (en) | 2002-09-10 |
| DE19951671A1 (de) | 2001-05-03 |
| BR0015112A (pt) | 2002-10-29 |
| HUP0203476A3 (en) | 2003-07-28 |
| KR20020047301A (ko) | 2002-06-21 |
| CZ20021485A3 (cs) | 2003-06-18 |
| JP2003512460A (ja) | 2003-04-02 |
| NO20021986L (no) | 2002-04-26 |
| BG106700A (en) | 2003-02-28 |
| WO2001030767A1 (de) | 2001-05-03 |
| HUP0203476A2 (en) | 2003-05-28 |
| CA2389012A1 (en) | 2001-05-03 |
| EP1228047A1 (de) | 2002-08-07 |
| CN1384822A (zh) | 2002-12-11 |
| IL149312A0 (en) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6362A (is) | Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni | |
| AU2426602A (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor | |
| BRPI0606455A (pt) | compostos farmacêuticos | |
| MXPA04003795A (es) | Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos. | |
| ATE286897T1 (de) | Morpholinderivate als antagonisten an orexinrezeptoren | |
| TR200101155T2 (tr) | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III | |
| AP9901442A0 (en) | 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists. | |
| CY1110243T1 (el) | Ανταγωνιστες npyy5 | |
| HUP0302435A2 (hu) | 11-Béta-hidroxiszteroid dehidrogenáz 1 típusú enzimet gátló anyagok és ezeket tartalmazó gyógyszerkészítmények | |
| AR018168A1 (es) | Antagonista de nociceptina que comprende un derivado de amida, composicion farmaceutica y analgesica que lo incluye, uso de dicho derivado de amida yenvase comercial que comprende dicha composicion farmaceutica | |
| TR200101893T2 (tr) | Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler. | |
| ATE219077T1 (de) | Endothelin antagoniste | |
| UY24938A1 (es) | Derivados de pirimidina y procedimientos para la preparación de los mismos | |
| TR200102540T2 (tr) | Heterosiklik bileşimler, ara ürünleri ve elastaz inhibitörleri. | |
| MXPA05009988A (es) | Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos. | |
| TR200201169T2 (tr) | 2-(4,6-Dimetilpirimidinil-2-oksi)-3- [2-(3,4-dimetoksifenil)etoksi]-3,3-difenilpropiyonat ve endotelin antagonist olarak kullanılması | |
| TR200003652T2 (tr) | Glisin antagonistleri olarak tetrahidrokuinolin türevleri. | |
| TR200103855T2 (tr) | Melagatranın büyük ölçüde kristalin bir formu. | |
| TR200101654T2 (tr) | Vitronektin reseptr antagonistleri | |
| DE60036558D1 (de) | Phthalazinon-derivate als pde 4 hemmer | |
| ATE250058T1 (de) | Crf rezeptor-antagonisten und darauf bezogene methoden | |
| EA200300226A1 (ru) | ГЕМ-ЗАМЕЩЕННЫЕ АНТАГОНИСТЫ ИНТЕГРИНА αvβ3 | |
| EP1533312A4 (en) | HETEROBICYCLIC COMPOUNDS | |
| MXPA05006587A (es) | Compuestos de tiazol como derivados de antagonistas del receptor de la integrina. | |
| ATE260918T1 (de) | Crf rezeptor-antagonisten und darauf bezogene methoden |